BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. stock has experienced significant volatility. In December 2024, shares plummeted nearly 80% after discontinuing a Phase 2 trial for azelaprag due to safety concerns. Despite this setback, the stock has shown signs of recovery, rising 14.44% compared to the previous week and 21.90% over the last month as of December 3, 2024. Over the past six months, the stock has shown a significant increase of 134.92% as of December 3, 2024. In October and November 2025, news articles highlighted the stock soaring, with Citigroup considering the obesity drugmaker's stock a "buy."

BioAge Labs, Inc. does not have commercialized products with established demand seasonality. The company's revenue is primarily generated through research and development activities, partnerships, and licensing agreements, rather than direct product sales to consumers. Therefore, typical demand seasonality patterns are not applicable to BioAge Labs' current business model.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the biological mechanisms of aging to extend healthy human lifespan. The company operates in the Biotechnology & Medical Research industry. BioAge Labs utilizes a platform integrating machine learning, omics data, and human biobanks to identify key molecular drivers of aging and age-related diseases. Its pipeline includes Azelaprag (BGE-102), an APJ agonist for obesity; BGE-102, an NLRP3 inhibitor for metabolic diseases; BGE-117, a HIF-PH inhibitor for anemia and muscle weakness; BGE-175, targeting the PGD2 DP1 pathway for immune function; and other APJ agonists for metabolic disorders.

BioAge Labs, Inc. is headquartered in Richmond, California, with some sources also listing Emeryville, California, as its headquarters. The company's primary operations are concentrated in the United States.

BioAge Labs' brand reputation was significantly impacted in December 2024 due to the discontinuation of a Phase 2 trial for azelaprag, leading to a stock price drop and an investigation by Hagens Berman. However, recent news from October and November 2025 indicates positive analyst sentiment, with Citigroup issuing a "buy" rating for the stock, suggesting a potential recovery or improvement in reputation.

BioAge Labs is primarily owned by institutional investors, who hold 58.71% of the shares, while insiders own 3.63%, and retail investors account for 37.66% of the ownership. Major institutional shareholders include AH Capital Management, L.L.C., Sofinnova Investments, Inc., Cormorant Asset Management, LP, ADAR1 Capital Management, LLC, Vanguard Group Inc, Tang Capital Management Llc, BlackRock, Inc., Orbimed Advisors Llc, Sands Capital Ventures, LLC, Geode Capital Management LLC, Marshall Wace LLP, Stonepine Capital Management LLC, Ameriprise Financial Inc., and Jefferies Financial Group Inc. CEO Kristen Fortney is also an insider owner, holding 3.4% of the company's shares.